EU body rejects Alzheimer’s drug by Biogen, Eisai
12:58 JST, December 18, 2021
BRUSSELS (Jiji Press) — The European Medicines Agency said Friday that it has recommended refusal of the marketing authorization for the new Alzheimer’s disease drug jointly developed by U.S. biopharmaceutical company Biogen Inc. and Japan’s Eisai Co. .
The European Union regulatory body could not confirm the effectiveness and safety of the drug, aducanumab, in clinical trials.
The drug, whose product name is Aduhelm, is drawing attention as the first medicine that acts on a substance believed to cause the disease.
Biogen said the same day that it will “seek a re-examination” by the EMA.
Japan’s health ministry plans to discuss whether to approve the drug at a panel meeting Wednesday.
The EMA said the link between the drug’s effectiveness in reducing the substance that causes the disease and clinical improvement “had not been established.”
“Results from the main studies were conflicting and did not show overall that Aduhelm was effective at treating adults with early stage Alzheimer’s disease,” the EMA said.
“In addition, the studies did not show that the medicine was sufficiently safe as images from brain scans of some patients showed abnormalities suggestive of swelling or bleeding, which could potentially cause harm, “ it added.
The drug was approved in the United States in June through fast-track procedures. The practical use of the drug already started in the country.
But its sales have been sluggish, as some people have questioned its effectiveness, informed sources said.
"World" POPULAR ARTICLE
-
Japan Prime Minister Seeks Cooperation Against Disinformation During Online Meeting of International Summit for Democracy
-
China Mutes Memorialization of Reformer Hu Yaobang; Memories Could Spark Critique of Xi Administration
-
Summer Sonic Music Festival to Be Held Also in Thailand
-
Search Continues for Missing People After 72-Hour Window Ends in Quake-Hit Taiwan; Weather Complicating Rescue Efforts
-
Japanese Director of U.N. Agency Gets First-Hand Look at Horrors, Broken Spirits of Gaza
JN ACCESS RANKING
- Japan Lags in Efforts to Gain Value from Human Resources; Govt Working to Increase Usage
- Bank of Japan Governor: Mortgages Not Expected to Rise Significantly After End to Negative Interest Rate Policy
- M6.0 Earthquake Hits Japan’s Tohoku Region; Fukushima, Iwate, Miyagi Prefectures Observe 4 on Japanese Scale With No Risk of Tsunami
- Cherry Blossoms Draw Crowd to Tokyo’s Ueno Park; Viewing Season Kicks Off to Slow Start
- Shohei Ohtani’s Former Interpreter Ippei Mizuhara Appears in School Textbook; Publisher Considers Replacing Content